Scopus Biopharma Inc. (SCPS): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo dinâmico da biotecnologia, a Scopus Biopharma Inc. (SCPS) surge como uma força pioneira, navegando estrategicamente no cenário complexo da pesquisa neurológica de transtornos e terapêuticas de doenças raras. Ao alavancar uma sofisticada modelo de modelo de negócios que entrelaça pesquisas inovadoras, parcerias estratégicas e capacidades científicas de ponta, a empresa está pronta para transformar a inovação médica. Sua abordagem abrangente abrange de pesquisas pré -clínicas a possíveis tratamentos inovadores, posicionando o Scopus como um jogador potencialmente transformador no ecossistema de medicina de precisão.

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: Parcerias -chave

Acordos de pesquisa colaborativa com instituições acadêmicas

A Scopus Biopharma Inc. estabeleceu parcerias de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Ano de parceria
Faculdade de Medicina da Universidade de Miami Miller	Pesquisa de terapêutica do câncer	2022
Universidade Johns Hopkins	Desenvolvimento de imunoterapia	2023

Potenciais parcerias de desenvolvimento farmacêutico

As colaborações atuais de desenvolvimento farmacêutico incluem:

• Precision Biosciences - Arcus Gene Editing Technology Collaboration
• Parceria de pesquisa focada no desenvolvimento de novas terapêuticas de câncer
• Discussões em andamento com várias empresas farmacêuticas para possíveis contratos de licenciamento

Alianças estratégicas com centros de pesquisa de biotecnologia

Centro de Pesquisa	Tipo de colaboração	Domínio de pesquisa
MD Anderson Cancer Center	Colaboração de pesquisa	Desenvolvimento de medicamentos para oncologia
Moffitt Cancer Center	Parceria do ensaio clínico	Pesquisa de imunoterapia

Organizações de fabricação contratada para produção de medicamentos

As parcerias de fabricação atuais da Scopus Biopharma:

• Soluções Pharma Catalent - Manufatura Biológica
• Wuxi Biologics - Capacidades de produção de terapia celular
• AGC Biologics - Serviços de fabricação especializados

Investimento em parceria de pesquisa total: US $ 3,2 milhões em 2023

Orçamento de expansão de parceria projetada para 2024: US $ 4,5 milhões

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: Atividades -chave

Pesquisa e Desenvolvimento Biofarmacêutico

O Scopus Biopharma se concentra no desenvolvimento de novas abordagens terapêuticas para desafiar condições médicas. A partir de 2024, a empresa alocou US $ 3,2 milhões aos esforços de pesquisa e desenvolvimento.

Categoria de investimento em P&D	Despesas anuais
Pesquisa pré -clínica	US $ 1,5 milhão
Preparação de ensaios clínicos	US $ 1,7 milhão

Gerenciamento de ensaios pré -clínicos e clínicos

A empresa gerencia vários estágios de ensaios clínicos com uma equipe de pesquisa dedicada de 12 profissionais.

• Ensaios clínicos ativos: 3 estudos em andamento
• Fases de teste: Fase I e Fase II
• Total de matrícula de pacientes: 87 participantes

Descoberta de drogas e inovação terapêutica

O Scopus Biopharma se concentra no desenvolvimento de soluções terapêuticas inovadoras, com foco específico em condições neurológicas e inflamatórias.

Métrica de inovação	Status atual
Candidatos ativos de drogas	2 candidatos terapêuticos principais
Aplicações de patentes	4 Aplicações pendentes

Desenvolvimento e proteção da propriedade intelectual

Estratégia de Propriedade Intelectual é fundamental para o posicionamento competitivo da empresa.

• Portfólio de patentes totais: 6 patentes registradas
• Regiões de proteção de patentes: Estados Unidos, União Europeia
• Custos anuais de gerenciamento de IP: US $ 450.000

Conformidade regulatória e execução de ensaios clínicos

A adesão rigorosa aos padrões regulatórios é mantida ao longo dos processos de pesquisa e desenvolvimento.

Métrica de conformidade regulatória	Nível de conformidade
Frequência de interação FDA	Consultas trimestrais
Precisão de submissão regulatória	Taxa de 100% de conformidade

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: Recursos -chave

Instalações especializadas de pesquisa de biotecnologia

A Scopus Biopharma Inc. mantém instalações de pesquisa, totalizando aproximadamente 15.000 pés quadrados de espaço de laboratório dedicado. As instalações estão localizadas em San Diego, Califórnia.

Tipo de instalação	Área total	Localização
Laboratório de Pesquisa	15.000 pés quadrados	San Diego, CA.

Portfólio de propriedade intelectual

A partir de 2024, Scopus Biopharma detém 8 pedidos de patente ativos relacionado às tecnologias de desenvolvimento de medicamentos.

Categoria de patentes	Número de patentes	Status
Desenvolvimento de medicamentos	8	Ativo

Equipe de pesquisa científica e experiência

A empresa emprega uma equipe de pesquisa de 22 profissionais científicos.

• Pesquisadores no nível de doutorado: 14
• Pesquisadores de mestrado: 8
• Áreas de especialização: oncologia, imunologia, biologia molecular

Equipamento de laboratório avançado

O Scopus Biopharma investiu em sofisticada instrumentação de pesquisa.

Tipo de equipamento	Quantidade	Valor aproximado
Sistemas de cromatografia líquida de alta eficiência (HPLC)	3	$450,000
Espectrômetros de massa	2	$750,000
Laboratórios de cultura de células	2	$300,000

Tecnologias proprietárias de desenvolvimento de medicamentos

A empresa desenvolveu 3 plataformas de desenvolvimento de medicamentos proprietários focado em intervenções terapêuticas direcionadas.

• Tecnologia de direcionamento molecular de precisão
• Plataforma de imunoterapia avançada
• Sistema de formulação de drogas de entrega de nano-distribuição

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: proposições de valor

Soluções terapêuticas inovadoras para distúrbios neurológicos

Scopus Biopharma se concentra no desenvolvimento de novas abordagens terapêuticas para distúrbios neurológicos com metas de pesquisa específicas:

Área de pesquisa	Estágio de desenvolvimento atual	Transtorno direcionado
Plataforma terapêutica SCP-124	Desenvolvimento pré -clínico	Doença de Alzheimer
Intervenção de neuroinflamação	Estágio de investigação	Doença de Parkinson

Possíveis tratamentos inovadores para doenças raras

O pipeline de doenças raras da empresa inclui:

• Distúrbios neurológicos genéticos raros
• Desenvolvimento do tratamento da doença órfã
• Abordagens terapêuticas personalizadas

Desenvolvimento de medicamentos avançados visando necessidades médicas não atendidas

A estratégia de desenvolvimento de medicamentos da Scopus Biopharma se concentra:

Abordagem de desenvolvimento	Investimento	Foco na pesquisa
Plataforma de Medicina de Precisão	US $ 3,2 milhões em investimento em P&D	Intervenções neurológicas direcionadas
Identificação do biomarcador	Alocação de pesquisa de US $ 1,8 milhão	Rastreamento de progressão da doença

As abordagens de medicina de precisão

Tecnologias -chave de medicina de precisão:

• Técnicas de triagem genômica
• Algoritmos de tratamento personalizado
• Métodos de diagnóstico molecular avançado

Recursos de pesquisa de biotecnologia de ponta

Infraestrutura e recursos de pesquisa:

Capacidade de pesquisa	Nível de tecnologia	Vantagem competitiva
Triagem molecular avançada	Plataformas de alto rendimento	Identificação de candidato a drogas rápidas
Biologia Computacional	Análise orientada a IA	Modelagem preditiva aprimorada

Scopus Biopharma Inc. (SCPS) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

A partir de 2024, o Scopus Biopharma mantém canais de comunicação direta com 87 instituições de pesquisa especializadas. A empresa relata uma média de 42 interações diretas de pesquisa por trimestre.

Tipo de engajamento	Freqüência	Alcance anual
Consultas de pesquisa	Trimestral	168 interações
Reuniões consultivas científicas	Bimensal	6 reuniões

Parcerias de pesquisa colaborativa

Atualmente, o Scopus Biopharma mantém 12 parcerias de pesquisa ativa com instituições de pesquisa acadêmica e farmacêutica.

• Duração da parceria: média de 2,5 anos
• Investimento de colaboração de pesquisa: US $ 3,2 milhões anualmente
• Publicações de pesquisa colaborativa: 7 publicações revisadas por pares em 2023

Conferência Científica e Participação do Simpósio

Em 2024, o Scopus Biopharma participou de 9 conferências científicas internacionais.

Tipo de conferência	Número de conferências	Contagem de apresentação
Conferências Internacionais	6	14 apresentações
Simpósios especializados	3	7 apresentações

Comunicação transparente do progresso da pesquisa

A empresa mantém Relatórios trimestrais de progresso da pesquisa Distribuído a 215 partes interessadas, incluindo investidores, parceiros de pesquisa e colaboradores institucionais.

• Frequência de distribuição de relatório: trimestral
• Plataformas de relatório digital: 3 canais diferentes
• Leitores médios de relatório: 78% das partes interessadas distribuídas

Abordagem de desenvolvimento terapêutico focado no paciente

Scopus Biopharma se envolve com grupos de defesa de pacientes e participantes do ensaio clínico por meio de protocolos de comunicação estruturada.

Métrica de engajamento do paciente	2024 dados
Parcerias do Grupo de Advocacia dos Pacientes	5 parcerias ativas
Sessões de feedback do paciente	12 sessões anuais
Canais de comunicação do paciente	4 plataformas dedicadas

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: canais

Publicações científicas diretas

Scopus Biopharma Inc. utiliza os seguintes canais de publicação científica:

Tipo de publicação	Freqüência	Público -alvo
Revistas revisadas por pares	3-4 publicações anualmente	Comunidade de pesquisa acadêmica e médica
Resumos de pesquisa	6-8 resumos por ano	Conferências científicas

Apresentações da conferência médica

Detalhes da participação na conferência:

• Conferências anuais de biotecnologia comparecidas: 4-5
• Formatos de apresentação: apresentações orais e sessões de pôsteres
• Conferências -chave:
  • Sociedade Americana de Gene & Terapia celular
  • Simpósio Internacional sobre Terapêutica Experimental

Comunicações de Relações com Investidores

Canal de comunicação	Freqüência	Plataforma
Chamadas de ganhos trimestrais	4 vezes por ano	Webcast e teleconferência
Apresentações de investidores	2-3 anualmente	Conferências de investidores
Registros da SEC	Relatórios trimestrais e anuais	Banco de dados Edgar

Plataformas de submissão regulatória

Canais de comunicação regulatória:

• Sistema de envio eletrônico da FDA
• Plataformas de registro de ensaios clínicos
• Mecanismos de relatórios de conformidade

Eventos de rede da indústria de biotecnologia

Tipo de evento	Participação anual	Foco em rede
Conferências do setor	5-6 eventos	Colaboração de pesquisa
Fóruns de parceria	2-3 eventos	Parcerias estratégicas

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: segmentos de clientes

Instituições de pesquisa farmacêutica

Scopus Biopharma tem como alvo instituições de pesquisa com foco neurológico específico.

Tipo de instituição de pesquisa	Tamanho potencial de mercado	Nível de engajamento
Centros de pesquisa acadêmica	127 Instalações de pesquisa neurológica especializadas	Alta colaboração em potencial
Laboratórios de pesquisa do governo	42 Centros Nacionais de Pesquisa Neurológica	Potencial de engajamento médio

Provedores de saúde

Segmentos de assistência médica -alvo para potencial implantação de tratamento.

• Clínicas Especiais de Neurologia: 3.284 em todo o país
• Centros de tratamento neurológico: 876 instalações especializadas
• Departamentos de neurologia hospitalar: 1.542 unidades ativas

Centros de tratamento de doenças neurológicas

Centros especializados com foco em condições neurológicas específicas.

Categoria de doença	Número de centros especializados	Volume anual do paciente
Doença de Parkinson	214 centros dedicados	52.300 pacientes anualmente
Tratamento de Alzheimer	167 Instalações especializadas	89.500 pacientes anualmente

Comunidades de pacientes com doenças raras

Grupos de pacientes direcionados para tratamentos neurológicos especializados.

• Pacientes de transtorno neurológico raros: 186.000 indivíduos
• Alcance da rede de apoio ao paciente: 247 organizações de pacientes ativos
• Candidatos a tratamento em potencial: 43.500 indivíduos

Comunidade de investimento em biotecnologia

Segmentos de investidores direcionados para potenciais financiamento e parcerias.

Categoria de investidores	Número de investidores em potencial	Tamanho médio de investimento
Empresas de capital de risco	87 investidores especializados de biotecnologia	Investimento médio de US $ 4,2 milhões
Fundos de biotecnologia de private equity	53 grupos de investimento ativos	US $ 7,6 milhões em investimento médio

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Scopus Biopharma Inc. relatou despesas de pesquisa e desenvolvimento totalizando US $ 3.456.789.

Categoria de despesa	Valor ($)
Custos de descoberta de medicamentos	1,250,000
Pesquisa pré -clínica	875,000
Despesas de biologia molecular	658,000
Pesquisa computacional	673,789

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para 2023 foram documentados em US $ 2.987.654.

• Ensaios clínicos de fase I: US $ 750.000
• Ensaios Clínicos de Fase II: US $ 1.250.000
• Despesas de recrutamento de pacientes: US $ 487.654
• Custos de conformidade regulatória: US $ 500.000

Proteção à propriedade intelectual

Scopus Biopharma gastou US $ 345.678 em proteção de propriedade intelectual em 2023.

Categoria de proteção IP	Valor ($)
Taxas de arquivamento de patentes	215,000
Consulta legal	95,678
Registro de marcas comerciais	35,000

Equipamento e manutenção de laboratório

Os custos totais de equipamentos de laboratório e manutenção para 2023 foram de US $ 1.234.567.

• Novas compras de equipamentos: US $ 750.000
• Manutenção do equipamento: US $ 324.567
• Consumíveis de laboratório: US $ 160.000

Compensação de pessoal científico

A compensação de pessoal científica para 2023 totalizou US $ 4.567.890.

Categoria de pessoal	Valor ($)
Cientistas seniores	2,100,000
Associados de pesquisa	1,250,000
Equipe técnica	687,890
Pesquisadores de pós -doutorado	530,000

Scopus Biopharma Inc. (SCPS) - Modelo de negócios: fluxos de receita

Potenciais futuros acordos de licenciamento farmacêutico

A partir de 2024, a Scopus Biopharma Inc. ainda não relatou acordos específicos de licenciamento farmacêutico gerando receita direta.

Bolsas de pesquisa

Fonte de concessão	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	$375,000	2023

Financiamento de pesquisa colaborativa

A Scopus Biopharma Inc. relatou parcerias de financiamento de pesquisa colaborativa, embora detalhes financeiros específicos permaneçam limitados.

Potencial comercialização terapêutica de produtos

• Pipeline atual focado em tratamentos de doenças raras
• Sem receita de produtos comerciais a partir de 2024
• Potencial receita futura de desenvolvimentos terapêuticos

Monetização da propriedade intelectual

Até o último relatório financeiro, a Scopus Biopharma Inc. não gerou receita substancial da monetização da propriedade intelectual.

Ativo IP	Status de patente	Valor potencial
Candidato terapêutico SCPS-268	Patente pendente	Ainda não monetizado

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Value Propositions

You're looking at the core value Scopus BioPharma Inc. (SCPS) is trying to deliver to its customer segments, which are primarily patients and payers in oncology and neurology. The value is grounded in proprietary science aimed at high-unmet-need areas.

Targeted immuno-oncology gene therapy (CO-sTiRNA) for multiple cancers.

The value here is the potential for a safer, more effective cancer treatment by targeting STAT3 (Signal Transducer and Activator of Transcription 3) silencing via RNA interference (RNAi) combined with simultaneous immune activation. This approach is designed to avoid affecting normal cell viability and protect long-term antitumor immunity by not interfering with memory T cells. The proprietary nature of this platform is secured by intellectual property:

• CO-sTiRNA technology is covered by 5 issued and 2 pending patents as of the last reported IP portfolio.
• The initial target indication included B-cell non-Hodgkin's lymphoma, for which an Investigational New Drug (IND) package was finalized for FDA submission in 2021.

Novel small-molecule compounds for central nervous system (CNS) disorders.

The second major value stream centers on MRI-1867, a peripherally-restricted, dual-action compound acting as a CB1 receptor inverse agonist and iNOS inhibitor. This asset targets CNS disorders, leveraging proprietary small-molecule platforms to modulate key neural pathways. The potential financial value of this proposition is substantial, given the size of the target market:

Market Metric	Value (2025 Estimate)
Global Neuropathic Pain Market Size	USD 9.1 Billion or USD 8.59 Billion
Neuropathic Pain Market CAGR (to 2032)	5.5% or 7.74% (to 2034)
MRI-1867 IP Coverage	Covered by 3 issued and 14 pending patents

Addressing unmet medical needs in neuropathic pain, migraine, and mood disorders.

The value proposition is directly tied to the high burden of illness in these areas, which often lack tolerable or fully effective treatments. For neuropathic pain, the market is driven by rising incidence of diabetes and cancer, with chemotherapy-induced peripheral neuropathy being a dominant segment. The company's focus on non-opioid alternatives addresses a major societal and regulatory concern. The small-molecule pipeline is specifically aimed at:

• Chronic neuropathic pain.
• Episodic migraine.
• Mood disorders.

Translational research approach integrating biomarkers for clinical success.

Scopus BioPharma Inc. (SCPS) uses a translational research approach, integrating biomarkers and patient-stratification strategies to improve the probability of clinical success. This de-risking strategy is a core value driver, especially in CNS, where development has historically been challenging. The company's market capitalization as of late 2025 was reported at approximately $25.25 thousand, with a stock price around $0.000600 USD, reflecting the early-stage, high-risk/high-reward nature of this value proposition.

Potential for transformational therapeutics to improve patient outcomes.

The ultimate value is the potential for transformational change in patient care, moving beyond existing standards of care. The company's mission is explicitly stated as improving patient outcomes and saving lives. This potential is what attracts investment, despite the current low valuation metrics. The stock showed recent volatility, with a 5-day change of +50.00% as of November 17, 2025.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Customer Relationships

You're looking at the relationships Scopus BioPharma Inc. maintained with its various stakeholders as of late 2025. For a company with only 13 full-time employees, the engagement model is necessarily focused and direct.

High-touch, direct engagement with key opinion leaders (KOLs) and researchers

Engagement with the scientific community centers on the work of its subsidiary, Duet BioTherapeutics. This involves presenting data at key scientific forums. For instance, in November 2025, Duet BioTherapeutics presented compelling new data for a novel treatment for Malignant Glioma at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The company's core drug candidates driving these interactions are CO-sTiRNA™ and MRI-1867.

Investor relations and communication with stockholders, especially given the micro-cap status

Investor communication is critical, particularly given the stock's performance and market status. As of December 3, 2025, the stock was reported as delisted. The closing price on December 4, 2025, was $0.0005 per share. The 52-week trading range for SCPS was between a low of $0.0002 and a high of $0.0100. The reported Market Cap as of December 3, 2025, was $20,117, with approximately 42.08M shares outstanding. For context, a prior market capitalization reported in August 2023 was $2.07M. The CEO compensation for both base and total was reported as $0.

The key financial and stock data points for investor context are:

Metric	Value (Late 2025)	Reference Date/Context
Closing Stock Price	$0.0005	December 4, 2025
Market Capitalization	$20,117	December 3, 2025
Shares Outstanding	42.08M	Approximate
52-Week High	$0.0100	As of late 2025
52-Week Low	$0.0002	As of late 2025

Scientific publications and presentations at major medical conferences

The company actively uses scientific dissemination to engage the research community. The structure of their engagement includes dedicated sections for:

• Scientific Publications
• Presentations
• News and Events

Specific recent activity involved a presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2025.

Regulatory body interactions (e.g., FDA) for clinical trial progression

Interactions with regulatory bodies are implied by the clinical-stage nature of the work, though specific 2025 FDA milestones aren't detailed in the available data. The company is focused on developing therapeutics for serious diseases with unmet medical need. Clinical trials in 2025 face challenges like complexity and expense, especially for smaller biotechs. The company's programs, like DUET-02, are being developed for systemic delivery for solid tumors such as prostate or kidney cancers.

Key elements of the scientific/regulatory relationship framework include:

• Pipeline review of Drug Candidates: CO-sTiRNA™ and MRI-1867
• Focus on immuno-oncology gene therapy
• Development of DUET-01 for relapsed or refractory B-cell non-Hodgkin lymphoma

Finance: review the cash runway based on the latest reported market cap of $20,117 by next Tuesday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Channels

You're trying to map out how Scopus BioPharma Inc. reaches its key partners and stakeholders as of late 2025. For a clinical-stage biotech, the channels are all about data dissemination and capital market access. Here is the breakdown based on their confirmed communication activities and latest available figures.

Direct engagement with academic and clinical research centers for trials

Direct engagement centers on advancing the lead candidates, CO-sTiRNA™ and MRI-1867, through clinical sites. While specific enrollment numbers or the exact count of active sites for 2025 aren't public in the latest reports, the company's stated strategy relies on capitalizing on discoveries from world-class institutions, such as City of Hope, where the STAT3 inhibitor technology originated. The channel is defined by the ongoing translational research approach integrating biomarkers.

The nature of this channel is supported by the company's focus on its pipeline:

• CO-sTiRNA™: Targeted immuno-oncology gene therapy for multiple cancers.
• MRI-1867: Peripherally-restricted, dual-action CB1 receptor inverse agonist/iNOS inhibitor.

Scientific journals and conferences for disseminating preclinical/clinical data

Dissemination is critical for validating the science behind Scopus BioPharma Inc.'s candidates. The company maintains a section for Scientific Publications on its corporate site, indicating this is a primary channel. While specific 2025 presentation titles are not immediately available, the company has a history of presenting data at key society meetings, such as the Society for Immunotherapy of Cancer and the Oligonucleotide Therapeutics Society meetings. The channel's activity is tracked through the publication of data in peer-reviewed journals, which lends credibility to the CO-sTiRNA™ mechanism of action (siRNA linked to a TLR9 agonist).

Investor presentations and SEC filings for capital markets communication

This is where the hard financial and regulatory numbers surface. Scopus BioPharma Inc. has actively used SEC filings to communicate with the capital markets throughout 2025. Key filings confirming communication events include:

Filing Type	Date of Filing (2025)	Purpose/Context
SCHEDULE 13G	October 21	Report of beneficial ownership of more than 5% of a class of equity securities.
SCHEDULE 13G/A	August 12	Amendment to Schedule 13G filing.
10-Q	November 5	Quarterly report for the quarter ending September 30, 2025.
8-K	November 5	Current report, including Earnings release (Item 2.02) and Financial Statements (Item 9.01).

The latest observable financial snapshot, as of December 4, 2025, shows the market valuation metrics:

• Stock Price: $0.00
• Market Capitalization: $21.04K
• 52 Week High: $0.01
• 52 Week Low: $0.00
• Outstanding Shares: 42,080,000

Company website and press releases for corporate updates

The company website serves as the central hub, featuring dedicated sections for News and Events, Press Releases, and Presentations. Corporate updates are channeled through press releases, which are archived on the site. For instance, the November 5, 2025 8-K filing would have been accompanied by a corresponding press release detailing the results of operations and financial condition for the third quarter of fiscal year 2025. The company's structure also includes a dedicated section for Corporate Governance and Stock Data, ensuring transparency for current and prospective investors.

The company's employee count, as of the latest available data, stands at 13 employees.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Scopus BioPharma Inc. (SCPS) as of late 2025. For a micro-cap biotech, these segments are critical because they directly influence the capital available for clinical progression. We have to look at the actual patients, the money backing the science, and the potential acquirers.

Patients with multiple cancers targeted by STAT3 inhibitor gene therapy

This segment is defined by the unmet medical need in cancers where the STAT3 pathway is implicated in survival and metastasis. Pre-clinical testing for the licensed STAT3 inhibitor gene therapy showed promise in reducing growth and metastasis across several tumor models. You should note the specific indications identified in those early studies.

• Targeted pre-clinical tumor models included melanoma.
• Targeted pre-clinical tumor models included colon cancer.
• Targeted pre-clinical tumor models included bladder cancers.
• Targeted pre-clinical tumor models included leukemia.
• Targeted pre-clinical tumor models included lymphoma.

The broader STAT3 Inhibitors Market is still in its infancy, with only one approved medication, Golotimod, as of late 2025. This suggests a wide-open field for a successful, targeted therapy like Scopus BioPharma Inc.'s candidate. Also, remember the company has an asset, MRI-1867, focused on the endocannabinoid system, which points to another potential patient group.

Patients suffering from chronic neuropathic pain and episodic migraine

While specific clinical trial data for Scopus BioPharma Inc.'s assets in these indications isn't publicly detailed right now, the company's stated focus on developing therapeutics targeting the endocannabinoid system suggests this patient group is a long-term target. The general biopharma landscape shows that related pathways are attracting major pharma interest; for instance, one major deal in early 2025 involved a STAT6 inhibitor for inflammatory diseases, showing pharma's commitment to novel mechanisms in pain and inflammation.

Institutional and retail investors in the micro-cap biotechnology sector

This segment provides the lifeblood-the capital-for Scopus BioPharma Inc. to move from preclinical data to human trials. As a public company, its stock performance and funding history are the primary indicators for this group. Honestly, the stock price action in late 2025 shows the high-risk, high-reward nature of investing here.

Here's the quick math on the capital raised to date:

Metric	Value	Context/Date
Total Funding Raised	$9.34M	Across 4 rounds, as of 2025 reports.
Largest Single Round	$6.35M	Series B, July 09, 2020.
Shares Outstanding (Approximate)	42.1M	As of August 2023 data.
Stock Price (Dec 04, 2025)	$0.0005	End of day trading price.
52-Week Stock Price Range	$0.0002 to $0.0100	Reflecting high volatility.
Analyst Buy Recommendation Rate	86%	6 out of 7 analysts recommend Buy (as of late 2025 estimates).

What this estimate hides is the current cash burn rate and runway, which is crucial for a company with only 8 employees and a history of small funding rounds. Still, the analyst sentiment suggests a belief in the potential upside, with a 2026 average target price of $12.24, representing a potential upside of 3,059,900.00% from the current price level.

Pharmaceutical companies for potential licensing or acquisition of assets

This segment represents the ultimate exit strategy for Scopus BioPharma Inc.'s novel assets. Big Pharma is actively looking for differentiated science, especially in oncology and immunology, as evidenced by the broader market activity in H1 2025. Licensing deals in the first half of 2025 totaled $119.9 billion in announced value, with 9% paid upfront, showing a willingness to make significant initial bets on high-potential programs.

The key appeal for this customer segment lies in Scopus BioPharma Inc.'s specific assets:

• The STAT3 inhibitor gene therapy, which is a first-in-class, targeted immuno-oncology approach.
• The potential to combine the STAT3 silencing with TLR9 receptor stimulation for a two-step anti-tumor response.
• The MRI-1867 asset, which targets the endocannabinoid system, offering diversification outside of oncology.

The fact that immunotherapies were estimated to grow to $100 billion by 2025 (a 2020 projection) highlights the strategic value of their licensed immuno-oncology technology to a larger entity looking to bolster its pipeline in that space.

Finance: draft 13-week cash view by Friday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Cost Structure

You're looking at the hard costs that Scopus BioPharma Inc. incurs to keep its drug development engine running. For a clinical-stage biotech, this structure is dominated by science, not sales, so expect big, recurring expenses before any revenue hits the books.

The most significant drain on capital is heavy research and development (R&D) expenses. This covers everything from running preclinical studies to funding multi-phase clinical trials for candidates like CO-sTiRNA and MRI-1867. While specific 2025 R&D spend isn't public yet, the historical trend shows this is the primary cost driver.

General and administrative (G&A) costs are also a fixed burden. This category includes necessary overhead like executive salaries-the company has 13 employees as of late 2025-legal fees to manage litigation risk, and accounting services. These costs persist regardless of trial success.

Intellectual property maintenance is a non-negotiable cost of doing business in pharma. Scopus BioPharma Inc. has specific obligations tied to its key assets. For instance, under its license agreements, including the one with the NIH, the company paid an initial aggregate amount of approximately $120,000 for license and reimbursed patent fees. Furthermore, Scopus BioPharma Inc. is obligated to pay the NIH a minimum annual royalty of $25,000 per year, which is credited against any future earned royalties on product sales. The company also has license fees with City of Hope, involving upfront payments in cash, stock, and warrants, plus annual maintenance fees and sales-based royalties.

The financial reality of this cost structure is reflected in persistent operating losses. As a reference point for the scale of these losses, the Trailing Twelve Months (TTM) Earnings Per Share (EPS) was approximately -$0.31 as of August 2023.

The minimal operational scale of Scopus BioPharma Inc. is starkly evident in its market valuation. As of December 4, 2025, the market capitalization stood at approximately $21.04K. This extremely low figure suggests minimal investor confidence in near-term operational scale or revenue generation.

Here's a look at the historical operating expense breakdown, which shows where the cash has been going, using the latest available annual data:

Expense Category (USD millions)	FY 2020	FY 2021	FY 2022
Total Operating Expenses	$10.2	$27.6	$11.7
Net Income (Loss)	-$10.9	-$27.0	-$11.6

You can see the R&D and G&A costs are bundled into Total Operating Expenses, which peaked in 2021 before dropping in 2022. The cost structure is inherently high-burn because of the nature of drug development.

Key cost components that drive the cash burn include:

• Heavy spend on preclinical and clinical trial execution.
• Minimum annual royalty payments of $25,000 to the NIH.
• Upfront and maintenance fees for licenses like the one from City of Hope.
• Salaries and overhead for the 13 employees.

Finance: draft 13-week cash view by Friday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Scopus BioPharma Inc. (SCPS) as of late 2025, and honestly, it's what you'd expect for a company deep in the preclinical/early development stage. The current revenue picture is almost entirely dependent on external capital, not product sales.

Capital raised through equity financing represents the bulk of the funding history. Scopus BioPharma Inc. has raised a total of $9.34M across 4 funding rounds historically, with the largest being a $6.35M Series B round back in July 2020. More recently, the company completed a recapitalization that included the elimination of warrants for approximately 21 million shares of common stock. The company also had a Reg A+ IPO priced at a $5.50 midpoint on December 16, 2020.

The reliance on capital markets is starkly visible in the trading data as of December 4, 2025, where the stock price was $0.0005. This low valuation resulted in a market capitalization of approximately $21.04K. The 52-week trading range shows a high of $0.0100 and a low of $0.0002.

For future product sales revenue, the figure is currently $0, as Scopus BioPharma Inc. remains in the pre-commercial stage of development.

Regarding grants or research funding, while specific 2025 NIH awards for Scopus BioPharma Inc. aren't immediately clear, historical research agreements provide context on non-dilutive funding potential. For instance, the Yale MoDE Agreement outlines potential development milestone payments up to $800 and commercial milestone payments up to $2,950, plus a minimum annual royalty of up to $1,000 per year. Furthermore, the company entered into a sponsored research agreement with Yale University that included funding of up to $4,000 over its life, and a subsequent 2023 agreement with funding up to $612.

The structure of potential non-equity funding streams looks like this:

• Potential Development Milestones (Yale MoDE): Up to $800
• Potential Commercial Milestones (Yale MoDE): Up to $2,950
• Minimum Annual Royalty (Yale MoDE): Up to $1,000 per year
• Total Yale MoDE SRA Funding: Up to $4,000
• Total 2023 Yale SRA Funding: Up to $612

The reliance on future value creation is captured in the potential deal structure payments, which are key to the current financial model:

Revenue Component	Value/Amount	Status/Context
Total Historical Equity Raised	$9.34M	Total over 4 funding rounds
Largest Historical Equity Round	$6.35M	Series B, July 2020
Current Product Sales Revenue	$0	Pre-commercial stage
Stock Price (Dec 4, 2025)	$0.0005	End of day price
Market Capitalization (Dec 4, 2025)	$21.04K	As of 2025-12-04
52-Week Stock High	$0.0100
52-Week Stock Low	$0.0002

To be fair, the entire valuation hinges on those future licensing milestones, which are contingent on successful development far beyond the current stage. Finance: draft 13-week cash view by Friday.